The European Commission Sends Statement of Objections to Teva

The European Commission (‘Commission’) has recently released a press release that the Commission sends a statement of objections to Teva over misuse of the patent system and disparagement of rival multiple sclerosis medicine.

The Commission has informed Teva of its preliminary view that the company has breached EU Antitrust Rules by engaging in practices intended to delay competition to its blockbuster medicine, Copaxone.

These consisted in artificially extending patent protection of Copaxone and systematically spreading misleading information about a competing product with a view to hinder its market entry and uptake.

You can reach further information here.

Kind regards,

Zumbul Attorneys at Law

info@zumbul.av.tr